{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:07:23Z","timestamp":1791176843642,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.vaccine.2009.09.125","type":"journal-article","created":{"date-parts":[[2009,11,12]],"date-time":"2009-11-12T10:17:06Z","timestamp":1258021026000},"page":"4091-4102","source":"Crossref","is-referenced-by-count":91,"title":["Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom"],"prefix":"10.1016","volume":"28","author":[{"given":"Yoon Hong","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff P.","family":"Garnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William John","family":"Edmunds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9267","key":"10.1016\/j.vaccine.2009.09.125_bib1","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(00)04646-8","article-title":"Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England","volume":"357","author":"Sasieni","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2009.09.125_bib2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2009.09.125_bib3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen? The international perspective","volume":"111","author":"Munoz","year":"2004","journal-title":"Int J Cancer"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2009.09.125_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1258\/0956462011924100","article-title":"European guideline for the management of anogenital warts","volume":"12","author":"von Krogh","year":"2001","journal-title":"Int J STD AIDS"},{"issue":"19","key":"10.1016\/j.vaccine.2009.09.125_bib5","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"FUTURE II Study Group","year":"2007","journal-title":"N Engl J Med"},{"issue":"9447","key":"10.1016\/j.vaccine.2009.09.125_bib6","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.vaccine.2009.09.125_bib7","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2009.09.125_bib8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1473-3099(07)70083-X","article-title":"Cost-effectiveness analyses of human papillomavirus vaccination","volume":"7","author":"Newall","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2009.09.125_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001648-200211000-00006","article-title":"The theoretical population-level impact of a prophylactic human papilloma virus vaccine","volume":"13","author":"Hughes","year":"2002","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.vaccine.2009.09.125_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2009.09.125_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.bjc.6603575","article-title":"Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland","volume":"96","author":"French","year":"2007","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.vaccine.2009.09.125_bib12","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1371\/journal.pmed.0030138","article-title":"Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses","volume":"3","author":"Barnabas","year":"2006","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.vaccine.2009.09.125_bib13","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/sj.bjc.6604023","article-title":"The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting","volume":"97","author":"Kim","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2009.09.125_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/j.1471-0528.2008.01743.x","article-title":"The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6\/11\/16\/18) in the UK","author":"Dasbach","year":"2008","journal-title":"BJOG"},{"key":"10.1016\/j.vaccine.2009.09.125_bib15","doi-asserted-by":"crossref","first-page":"a769","DOI":"10.1136\/bmj.a769","article-title":"Economic evaluation of human papillomavirus vaccination in the United Kingdom","volume":"337","author":"Jit","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2009.09.125_bib16","article-title":"Estimating progression rates for human papillomavirus infection from epidemiological data","author":"Jit","year":"2009","journal-title":"Med Decis Making"},{"issue":"7","key":"10.1016\/j.vaccine.2009.09.125_bib17","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1158\/1055-9965.EPI-06-0129","article-title":"Human papillomavirus infections with multiple types and risk of cervical neoplasia","volume":"15","author":"Trottier","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.vaccine.2009.09.125_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.virol.2003.12.019","article-title":"Evidence for the coexistence of two genital HPV types within the same host cell in vitro","volume":"321","author":"McLaughlin-Drubin","year":"2004","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.vaccine.2009.09.125_bib19","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1086\/516784","article-title":"A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion","volume":"195","author":"Plummer","year":"2007","journal-title":"J Infect Dis"},{"issue":"9580","key":"10.1016\/j.vaccine.2009.09.125_bib20","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/S0140-6736(07)60947-7","article-title":"Papillomavirus vaccines in perspective","volume":"369","author":"Kahn","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.vaccine.2009.09.125_bib21","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1086\/521679","article-title":"Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine","volume":"196","author":"Giuliano","year":"2007","journal-title":"J Infect Dis"},{"issue":"9580","key":"10.1016\/j.vaccine.2009.09.125_bib22","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2009.09.125_bib23","unstructured":"Office for National Statistics. Mortality statistics: cause (series DH2). http:\/\/www.statistics.gov.uk\/statbase\/Product.asp?vlnk=618."},{"issue":"3","key":"10.1016\/j.vaccine.2009.09.125_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/imammb\/11.3.161","article-title":"Balancing sexual partnerships in an age and activity stratified model of HIV transmission in heterosexual populations","volume":"11","author":"Garnett","year":"1994","journal-title":"IMA J Math Appl Med Biol"},{"issue":"9296","key":"10.1016\/j.vaccine.2009.09.125_bib25","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(01)06885-4","article-title":"Sexual behaviour in Britain: early heterosexual experience","volume":"358","author":"Wellings","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2009.09.125_bib26","unstructured":"Department of Health Statistical Bulletin. Cervical screening programme, England: 2005\u201306. The Information Centre; 6.10.2007. http:\/\/www.ic.nhs.uk\/pubs\/csp0506 [accessed 20.12.2006]."},{"issue":"10","key":"10.1016\/j.vaccine.2009.09.125_bib27","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-132-10-200005160-00009","article-title":"Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review","volume":"132","author":"Nanda","year":"2000","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.vaccine.2009.09.125_bib28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.AOG.0000296488.85807.b3","article-title":"Liquid compared with conventional cervical cytology: a systematic review and meta-analysis","volume":"111","author":"Arbyn","year":"2008","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.vaccine.2009.09.125_bib29","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1471-0528.2007.01261.x","article-title":"Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales","volume":"114","author":"Martin-Hirsch","year":"2007","journal-title":"BJOG"},{"issue":"5","key":"10.1016\/j.vaccine.2009.09.125_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1365-2303.2003.00082.x","article-title":"Long-term follow-up of patients following negative colposcopy: a new gold standard and its implications for cervical screening","volume":"14","author":"Da Forno","year":"2003","journal-title":"Cytopathology"},{"key":"10.1016\/j.vaccine.2009.09.125_bib31","unstructured":"Eggington S, Hadwin R, Brennan A, Walker P. Modelling the Impact of Referral guideline changes for mild dyskaryosis on colposcopy services in England. NHSCSP publication no. 24; 2006. Sheffield, NHS Cancer Screening Programmes."},{"issue":"3","key":"10.1016\/j.vaccine.2009.09.125_bib32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/sj.bjc.6602002","article-title":"The predicted effect of changes in cervical screening practice in the UK: results from a modelling study","volume":"91","author":"Canfell","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2009.09.125_bib33","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/bmj.39363.471806.BE","article-title":"Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study","volume":"335","author":"Strander","year":"2007","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.vaccine.2009.09.125_bib34","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0306-5456(00)00098-X","article-title":"Hysterectomy prevalence and adjusted cervical and uterine cancer rates in England and Wales","volume":"108","author":"Redburn","year":"2001","journal-title":"BJOG"},{"issue":"1","key":"10.1016\/j.vaccine.2009.09.125_bib35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/sj.bjc.6603210","article-title":"HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial","volume":"95","author":"Kitchener","year":"2006","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.vaccine.2009.09.125_bib36","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1128\/JCM.33.8.2058-2063.1995","article-title":"Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts","volume":"33","author":"Greer","year":"1995","journal-title":"J Clin Microbiol"},{"issue":"10","key":"10.1016\/j.vaccine.2009.09.125_bib37","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1128\/JCM.37.10.3316-3322.1999","article-title":"Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients","volume":"37","author":"Brown","year":"1999","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2009.09.125_bib38","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bjc.6603955","article-title":"Prevalence of human papillomavirus antibodies in young female subjects in England","volume":"97","author":"Jit","year":"2007","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.vaccine.2009.09.125_bib39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/scbi.1999.0146","article-title":"The serological response to papillomaviruses","volume":"9","author":"Dillner","year":"1999","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"10.1016\/j.vaccine.2009.09.125_bib40","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.09.125_bib41","series-title":"Numerical REcipes in C++: the art of scientific computing","author":"Press","year":"2002"},{"key":"10.1016\/j.vaccine.2009.09.125_bib42","unstructured":"Office for National Statistics. Cancer statistics 2004: registrations series MB1 no. 35. http:\/\/www.statistics.gov.uk\/statbase\/Product.asp?vlnk=8843&More=N."},{"issue":"48","key":"10.1016\/j.vaccine.2009.09.125_bib43","first-page":"30","article-title":"Trends in anogenital warts and anogenital herpes simplex virus infection in the United Kingdom: 1996 to 2005","volume":"16","author":"Health Protection Agency","year":"2006","journal-title":"CDR Weekly"},{"issue":"48\u201349","key":"10.1016\/j.vaccine.2009.09.125_bib44","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1016\/j.vaccine.2005.06.034","article-title":"Costs of running a universal adolescent hepatitis B vaccination programme","volume":"23","author":"Wallace","year":"2005","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.vaccine.2009.09.125_bib45","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2009.09.125_bib46","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.vaccine.2006.05.116","article-title":"Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes","volume":"24","author":"Garnett","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2009.09.125_bib47","first-page":"220","article-title":"Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign","volume":"5","author":"Trotter","year":"2002","journal-title":"Commun Dis Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2009.09.125_bib48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/aje\/kwm086","article-title":"Multiparameter calibration of a natural history model of cervical cancer","volume":"166","author":"Kim","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"11","key":"10.1016\/j.vaccine.2009.09.125_bib49","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.vaccine.2009.09.125_bib50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2050","article-title":"The natural history of cervical HPV infection: unresolved issues","volume":"7","author":"Woodman","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.vaccine.2009.09.125_bib51","series-title":"Poster presented at the 25th international papillomavirus conference","article-title":"Unmasking HPV genotypes as impact of HPV vaccination","author":"Choi","year":"2009"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09014856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09014856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T16:11:22Z","timestamp":1590250282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09014856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":51,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0264410X09014856"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.09.125","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}